Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication



Trade name Simponi targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule: a TNF inhibitor. 



Golimumab reduces C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates effective modulation of inflammatory markers and bone metabolism.



Pregnancy category US: N (Not classified yet)



It binds to both soluble and transmembrane forms of TNFα. 



It is used as  a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.



Aadministered subcutaneous injection or by intravenous injection.



Approved as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.



In a large, double-blind randomized controlled trials in patients with rheumatoid arthritis golimumab in combination with methotrexate was more effective than methotrexate alone.



Among children and young adults with newly diagnosed type 1  diabetes results were better for endogenous insulin production and less exogenous insulin use than placebo.



Leave a Reply

Your email address will not be published. Required fields are marked *